BriaCell Therapeutics Stock Discussion

$BriaCell Therapeutics (BCTX.US)$
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
SABCS® "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes
Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median overall survival calcula...

$BriaCell Therapeutics (BCTX.US)$ BriaCell 2024 SABCS Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
GlobeNewswire· 6 mins
SABCS "Spotlight" poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer patient subtypes Median overall survival of 13.4 months exceeds historical controls. Phase 2 final median o...

$BriaCell Therapeutics (BCTX.US)$
👀

$BriaCell Therapeutics (BCTX.US)$ Reuters
2 mins ago
Briacell Announces First Patient Dosed With Bria-Ots™ in Metastatic Breast Cancer Study

$BriaCell Therapeutics (BCTX.US)$ Low risk at these prices. I can place my SLO below 0.45 or 0.40. This is very oversold and showing Bullish Divergence imo.

$BriaCell Therapeutics (BCTX.US)$ ok what's up why it fall

$BriaCell Therapeutics (BCTX.US)$ BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
1 MINUTE AGO, 7:50 AM EST
VIA GLOBENEWSWIRE
BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models
Novel therapy activates both innate and adaptive immune systems
Proof of concept Phase 1/2 Study of Bria-BRES™ in met...

$BriaCell Therapeutics (BCTX.US)$ BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
3 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
Multiple outperforming patients with overall survival of over 2 years
Survival benefit observed even in heavily pre-treated patients w...

$BriaCell Therapeutics (BCTX.US)$
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
▪️55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
▪️Multiple outperforming patients with overall survival of over 2 years
▪️Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhib...